Conference Schedules, Stock Price Movements, Executive Transitions, and Revenue Outlook - Research Report on Incyte, ViroPharma,

   Conference Schedules, Stock Price Movements, Executive Transitions, and
 Revenue Outlook - Research Report on Incyte, ViroPharma, Cooper, Varian and
                                PDL BioPharma

PR Newswire

NEW YORK, December 30, 2013

NEW YORK, December 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Incyte
Corporation (NASDAQ: INCY), ViroPharma Inc. (NASDAQ: VPHM), The Cooper
Companies Inc. (NYSE: COO), Varian Medical Systems Inc. (NYSE: VAR) and PDL
BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Incyte Corporation Research Report

On December 18, 2013, Incyte Corp. (Incyte) announced that it is scheduled to
present at the 32^nd Annual J. P. Morgan Healthcare Conference on January 13,
2014 at 8:30 a.m. PST/11:30 a.m. EST in San Francisco. The Company added that
the presentation will be webcast live and can be accessed at its website under
"Investor Relations, Events and Webcasts". The Full Research Report on Incyte
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/076e_INCY

--

ViroPharma Inc. Research Report

On December 24, 2013, ViroPharma Inc. (ViroPharma) stock rose to end the day
at $49.86, compared to the previous day's closing price of $49.83. The
Company's stock went up by 0.18% over the past three trading days, compared to
the Nasdaq Composite, which gained 2.40% during the same trading period. The
Full Research Report on ViroPharma Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/c730_VPHM

--

The Cooper Companies Inc. Research Report

On December 18, 2013, The Cooper Companies Inc. (Cooper) reported that it will
present at the 32^nd Annual J.P. Morgan Healthcare Conference in San Francisco
on January 14, 2014 at 2:30 p.m. PT/5:30 p.m. ET. Cooper stated that President
and CEO Robert S. Weiss, and Vice President and Chief Strategy Officer, Albert
G. White, III, will speak on behalf of the Company. The Company added that
live audio webcast of the presentation can be accessed via the Investor
Relations section of its website. The Full Research Report on The Cooper
Companies Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=  

http://www.analystscorner.com/r/full_research_report/9cde_COO

--

Varian Medical Systems Inc. Research Report

On December 16, 2013, Varian Medical Systems Inc. (Varian) announced the
retirement of Robert H. Kluge as the Company's Senior Vice President and
President, Imaging Components Businesses, effective February 7, 2014. Varian
informed that Sunny Sanyal, CEO of T-System, has been named by the Company CEO
Dow R. Wilson and appointed by the Board of Directors to assume the position
of Mr. Kluge, effective February 3, 2014. Wilson commented, "We are indebted
to Bob for his strategic vision, intelligent management, and consistent
execution that have propelled Varian to a leadership position in the global
imaging industry. He has set the stage for continued success and growth in our
components businesses." He further added, "Sunny Sanyal is an experienced
leader who will work with our seasoned imaging components management team to
expand and capitalize on the growth potential for these businesses. We look
forward under Sunny's leadership to building these businesses into a billion
dollar platform for Varian." The Full Research Report on Varian Medical
Systems Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/bd48_VAR

--

PDL BioPharma, Inc. Research Report

On December 10, 2013, PDL BioPharma, Inc. (PDL) announced its revenue guidance
for Q4 2013. The Company stated that it anticipates approximately $109 million
in revenues, as compared with actual revenue of $86 million for the Q4 2012,
representing a 26.7% YoY increase. The Company stated that the forecasted
revenue growth is driven by increased Q3 2013 sales for Avastin®, Herceptin®,
Lucentis®, Xolair®, Kadcyla®, Perjeta®, and Actemra® for which PDL receives
royalties in the Q4 2013, along with the addition of the royalty payments from
the Company's purchase of Depomed's diabetes-related royalties. According to
PDL, revenue guidance for Q4 2013 is net of an estimated payment due under the
Company's February 2011 settlement agreement with Novartis AG. The Full
Research Report on PDL BioPharma, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/066b_PDLI

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)